312 related articles for article (PubMed ID: 33581130)
1. Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity.
Zhang Z; Du Z; Liu Q; Wu T; Tang Q; Zhang J; Huang C; Huang Y; Li R; Li Y; Zhao Y; Zhang G; Zhou J; Huang H; Fang Z; He J
Metabolism; 2021 May; 118():154728. PubMed ID: 33581130
[TBL] [Abstract][Full Text] [Related]
2. PXR prevents cholesterol gallstone disease by regulating biosynthesis and transport of bile salts.
He J; Nishida S; Xu M; Makishima M; Xie W
Gastroenterology; 2011 Jun; 140(7):2095-106. PubMed ID: 21354151
[TBL] [Abstract][Full Text] [Related]
3. Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice.
Stroeve JH; Brufau G; Stellaard F; Gonzalez FJ; Staels B; Kuipers F
Lab Invest; 2010 Oct; 90(10):1457-67. PubMed ID: 20531290
[TBL] [Abstract][Full Text] [Related]
4. Activation of Constitutive Androstane Receptor Prevents Cholesterol Gallstone Formation.
Cheng S; Zou M; Liu Q; Kuang J; Shen J; Pu S; Chen L; Li H; Wu T; Li R; Li Y; Jiang W; Zhang Z; He J
Am J Pathol; 2017 Apr; 187(4):808-818. PubMed ID: 28283178
[TBL] [Abstract][Full Text] [Related]
5. FXR Signaling-Mediated Bile Acid Metabolism Is Critical for Alleviation of Cholesterol Gallstones by
Ye X; Huang D; Dong Z; Wang X; Ning M; Xia J; Shen S; Wu S; Shi Y; Wang J; Wan X
Microbiol Spectr; 2022 Oct; 10(5):e0051822. PubMed ID: 36036629
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine.
Kim I; Ahn SH; Inagaki T; Choi M; Ito S; Guo GL; Kliewer SA; Gonzalez FJ
J Lipid Res; 2007 Dec; 48(12):2664-72. PubMed ID: 17720959
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.
Schmitt J; Kong B; Stieger B; Tschopp O; Schultze SM; Rau M; Weber A; Müllhaupt B; Guo GL; Geier A
Liver Int; 2015 Apr; 35(4):1133-1144. PubMed ID: 25156247
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition protects against diet-induced gallstone formation through modulation of cholesterol and bile acid homeostasis.
Lee EJ; Kim MH; Kim YR; Park JW; Park WJ
Int J Mol Med; 2018 Mar; 41(3):1715-1723. PubMed ID: 29286073
[TBL] [Abstract][Full Text] [Related]
9. Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice.
Ikpa PT; Doktorova M; Meijsen KF; Nieuwenhuijze NDA; Verkade HJ; Jonker JW; de Jonge HR; Bijvelds MJC
Cell Mol Gastroenterol Hepatol; 2020; 9(1):47-60. PubMed ID: 31470114
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol-lowering effects of taurine through the reduction of ileal FXR signaling due to the alteration of ileal bile acid composition.
Miyata M; Tanaka T; Takahashi K; Funaki A; Sugiura Y
Amino Acids; 2021 Oct; 53(10):1523-1532. PubMed ID: 34596761
[TBL] [Abstract][Full Text] [Related]
11. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
Modica S; Petruzzelli M; Bellafante E; Murzilli S; Salvatore L; Celli N; Di Tullio G; Palasciano G; Moustafa T; Halilbasic E; Trauner M; Moschetta A
Gastroenterology; 2012 Feb; 142(2):355-65.e1-4. PubMed ID: 22057115
[TBL] [Abstract][Full Text] [Related]
12. Hepatic cholesterol accumulation ascribed to the activation of ileum Fxr-Fgf15 pathway inhibiting hepatic Cyp7a1 in high-fat diet-induced obesity rats.
Duan Y; Zhang F; Yuan W; Wei Y; Wei M; Zhou Y; Yang Y; Chang Y; Wu X
Life Sci; 2019 Sep; 232():116638. PubMed ID: 31288013
[TBL] [Abstract][Full Text] [Related]
13. Hyodeoxycholic acid attenuates cholesterol gallstone formation via modulation of bile acid metabolism and gut microbiota.
Shen S; Huang D; Qian S; Ye X; Zhuang Q; Wan X; Dong Z
Eur J Pharmacol; 2023 Sep; 955():175891. PubMed ID: 37429516
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis.
Li T; Matozel M; Boehme S; Kong B; Nilsson LM; Guo G; Ellis E; Chiang JY
Hepatology; 2011 Mar; 53(3):996-1006. PubMed ID: 21319191
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome Proliferator-Activated Receptor-
Wang G; Han T; Wang S; Chen M; Sun Y; Fu Z
Biomed Res Int; 2018; 2018():7475626. PubMed ID: 30105244
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast Growth Factor 21 Response in a Preclinical Alcohol Model of Acute-on-Chronic Liver Injury.
Christidis G; Karatayli E; Hall RA; Weber SN; Reichert MC; Hohl M; Qiao S; Boehm U; Lütjohann D; Lammert F; Karatayli SC
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360670
[TBL] [Abstract][Full Text] [Related]
17. Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk.
Al-Aqil FA; Monte MJ; Peleteiro-Vigil A; Briz O; Rosales R; González R; Aranda CJ; Ocón B; Uriarte I; de Medina FS; Martinez-Augustín O; Avila MA; Marín JJG; Romero MR
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):2927-2937. PubMed ID: 29883717
[TBL] [Abstract][Full Text] [Related]
18. Hypothyroidism Increases Cholesterol Gallstone Prevalence in Mice by Elevated Hydrophobicity of Primary Bile Acids.
Kube I; Tardio LB; Hofmann U; Ghallab A; Hengstler JG; Führer D; Zwanziger D
Thyroid; 2021 Jun; 31(6):973-984. PubMed ID: 33231505
[No Abstract] [Full Text] [Related]
19. Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice.
de Boer JF; Schonewille M; Boesjes M; Wolters H; Bloks VW; Bos T; van Dijk TH; Jurdzinski A; Boverhof R; Wolters JC; Kuivenhoven JA; van Deursen JM; Oude Elferink RPJ; Moschetta A; Kremoser C; Verkade HJ; Kuipers F; Groen AK
Gastroenterology; 2017 Apr; 152(5):1126-1138.e6. PubMed ID: 28065787
[TBL] [Abstract][Full Text] [Related]
20. Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization.
Uppal H; Zhai Y; Gangopadhyay A; Khadem S; Ren S; Moser JA; Xie W
Hepatology; 2008 Apr; 47(4):1331-42. PubMed ID: 18318438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
